(Q39470931)

English

Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab

scientific article published on 17 August 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab (English)

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

1 reference

based on heuristic

inferred from title

9

object named as

Jeffrey Schlom

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Augusto Orlandi

7

object named as

Augusto Orlandi

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

author name string

Swati Khanna

1

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Anish Thomas

2

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Daniel Abate-Daga

3

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Jingli Zhang

4

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Betsy Morrow

5

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Seth M Steinberg

6

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Patrizia Ferroni

8

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Fiorella Guadagni

10

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Raffit Hassan

11

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

publication date

17 August 2016

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Journal of Thoracic Oncology

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

11

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

11

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

1993-2005

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Immunotherapies for non-small-cell lung cancer and mesothelioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Fcgamma receptors as regulators of immune responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Advances in malignant mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Sera from patients with malignant mesothelioma can contain autoantibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

15 June 2018

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

17 June 2018

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

17 June 2018

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

17 June 2018

Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

21 August 2018

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

21 August 2018

Value of mesothelin immunostaining in the diagnosis of mesothelioma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

21 August 2018

A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

21 August 2018

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5075512

4 November 2018

Lymphocytic infiltration of pleural mesothelioma and its significance for survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/27544053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Malignant pleural mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27544053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Localised spontaneous regression in mesothelioma -- possible immunological mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/27544053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/27544053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27544053

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.JTHO.2016.07.033

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39470931&oldid=2206090696"